Cantargia develops antibody based therapies against the target IL1RAP. The two clinical programs are nadunolimab in phase II development for treatment of cancer, and CAN10 in phase I development for autoimmune/inflammatory diseases.
Company Details
- Employees
- 30
- Founded
- 2010
- Address
- Scheelevägen 27, Lund,skåne County 22363,sweden
- Phone
- 46 4 62 75 62 60
- in****@****gia.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- cantargia.com
- HQ
- Lund, Skåne County
Cantargia Ab Questions
Cantargia Ab's helpline number is 46 4 62 75 62 60
Cantargia Ab's website is cantargia.com
Cantargia Ab's LinkedIn profile is https://se.linkedin.com/company/cantargia-ab
Cantargia Ab has
30 employees.
View email and phone details for 30
employees at Cantargia Ab.
Cantargia Ab's industry is
Biotechnology Research
Cantargia Ab's top competitors are
Bioinvent International Ab,
Immunovia Ab,
Xintela Ab,
Biogaia Ab,
Hansa Biopharma,
Bioarctic,
Galenica Ab,
Camurus,
Genovis,
Alligator Bioscience Ab.
Cantargia Ab's support email address is info@cantargia.com
Cantargia Ab's categories are Biotechnology Research
Cantargia Ab's founding year is 2010
